On Wednesday, JPMorgan reiterated its Overweight rating on Abbott Laboratories (NYSE:ABT) with a steady price target of $135.00. The firm's assessment followed the company's recent quarterly earnings, highlighting a robust performance in its Medical Devices division and an unexpected boost from Covid testing, which balanced out one-time channel destocking in Overseas Pediatrics and a significant foreign exchange (FX) headwind.
Abbott Laboratories reported sales of $10.64 billion, marking a 4.9% increase as reported and an 8.2% rise on an organic basis excluding COVID impacts. This figure surpassed the reported consensus but fell short of organic expectations. Nevertheless, the company's earnings per share (EPS) of $1.21 edged out estimates by one cent. JPMorgan pointed out the resilience of Abbott in the face of approximately $0.30 of FX headwinds year-to-date, which translates to roughly 9%, suggesting that the company's underlying margin expansion is more substantial than it appears.
The financial institution's commentary emphasized confidence in Abbott's potential for another year of high-single-digit growth. This optimism is supported by continued strong performances in key franchises, including Structural Health, Electrophysiology, and Diabetes. According to JPMorgan, these factors position Abbott alongside other premium MedTech companies in their coverage.
Furthermore, JPMorgan noted that Abbott's current multiple of 23.0x estimated 2025 earnings represents a considerable discount when compared to other high-growth peers in the sector. The firm's stance is that Abbott's healthy fundamentals and reasonable valuation make it an attractive investment opportunity, and they advocate purchasing shares in light of the company's solid financial outlook.
In other recent news, Abbott Laboratories reported notable third-quarter financial results, including sales of $10.6 billion, surpassing consensus estimates. The robust performance was largely driven by its Medical Technology division and COVID-19 tests revenue. Despite challenges in international nutrition and its Core Laboratory business, the company reaffirmed its full-year 2024 organic growth guidance and even increased the midpoint of its earnings per share (EPS) range.
Investment banking firm Jefferies raised the price target for Abbott Laboratories to $125, maintaining a Hold rating, while Stifel financial firm increased its price target to $130, maintaining a Buy rating. These adjustments follow the company's strong third-quarter performance and promising growth outlook.
Abbott Laboratories' CEO, Robert Ford (NYSE:F), projects high single-digit revenue growth and double-digit earnings growth moving towards 2025. The company's Medical Device segment, accounting for approximately 45% of sales, is expected to drive this growth, particularly with new products in the Diabetes Care and Structural Heart markets.
Diabetes Care sales surpassed $1.6 billion, marking a 21% increase. Additionally, a new $7 billion share repurchase program was authorized, reflecting the company's confidence in its financial health and future prospects. These are among the recent developments at Abbott Laboratories.
InvestingPro Insights
Abbott Laboratories' strong performance highlighted by JPMorgan is further supported by real-time data from InvestingPro. The company's market capitalization stands at an impressive $205.29 billion, reflecting its significant presence in the healthcare sector. Abbott's revenue for the last twelve months as of Q2 2024 reached $40.73 billion, with a modest growth of 1.24%, aligning with JPMorgan's assessment of the company's resilience in the face of challenges.
InvestingPro Tips reveal that Abbott has maintained dividend payments for 54 consecutive years and has raised its dividend for 11 consecutive years. This track record of consistent dividend growth underscores the company's financial stability and commitment to shareholder returns, which may be particularly appealing to income-focused investors.
The company's P/E ratio of 37.18 and P/E ratio (Adjusted) of 34.67 for the last twelve months as of Q2 2024 suggest that investors are willing to pay a premium for Abbott's shares, possibly due to its strong market position and growth prospects in key areas like Medical Devices and Diabetes care, as noted in JPMorgan's analysis.
For readers interested in a more comprehensive analysis, InvestingPro offers 12 additional tips that could provide deeper insights into Abbott Laboratories' investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.